Medicare’s Unused Organ Payments: A $380 Million Oversight

Medicare paid an estimated $380 million over a 6-year period for acquiring organs that weren’t transplanted in Medicare enrollees because of conflicting federal program rules, according to a report from the HHS Office of Inspector General.

Audit Findings

Fifty-five of the 180 sampled organs were not used in Medicare-covered transplants even though they were reported as Medicare usable organs, which resulted in $2,847,855 in Medicare reimbursement to certified transplant centers (CTCs). Based on these sample results, it is estimated that CTCs received approximately $379,895,793 for organs that were not used in transplants covered by Medicare.

Medicare reimbursed the transplant centers over $3 billion for the acquisition of approximately 39,000 organs in calendar year 2023. Medicare’s reimbursement policy entails covering costs for acquiring viable human kidneys, livers, hearts, lungs, pancreases, and intestines.

Regulatory Conflicts

Federal law limits Medicare’s reimbursement to the cost of acquiring organs that are transplanted into Medicare enrollees, also known as ‘Medicare usable organs.’ The OIG conducted the audit to ascertain how much Medicare paid transplant centers for organs that were not actually transplanted into Medicare enrollees.

Using data from the CMS Healthcare Cost Report Information System, the OIG identified all Medicare cost reports from hospitals with transplant centers that had reporting periods between 2017 and 2022. The audit sample included 180 Medicare usable organs with associated Medicare reimbursements totaling $12,288,194 across 12 transplant centers.

Of the sampled organs, 125 were used in Medicare-covered transplants, while 43 were used in non-Medicare transplants, and 12 were never transplanted despite being reported as usable organs, amounting to $2.85 million in improper Medicare reimbursements.

Suggested Improvements

The OIG indicated that much of the issue arises from conflicting Medicare transplant payment rules. Suggestions for improvement include revising CMS guidance to align it with the Social Security Act, ensuring reimbursement is only for organs transplanted into Medicare recipients. CMS has stated it would consider these recommendations.

Broader Implications

This report raises questions about the coordination of federal oversight in organ transplantation. Experts, including Macey Levan from NYU Grossman School of Medicine, emphasize that stronger coordination is crucial for addressing such inconsistencies in the organ procurement system.

The findings come against the backdrop of ongoing controversies regarding the organ transplant system in the U.S., including concerns over the practices of organ procurement organizations and the transportation of organs away from their original geographic areas.

Disclaimer

Information provided in this article is for educational purposes only and should not be considered medical advice. Always consult a healthcare professional for personalized medical advice.

Fuente: https://www.medpagetoday.com/publichealthpolicy/medicare/122933